Dietary Transforming Growth Factor-Beta 2 (TGF-β2) Supplementation Reduces Methotrexate-Induced Intestinal Mucosal Injury in a Rat
Authors:
Open Access
- 12 September 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (9) , e45221
Abstract
Dietary supplementation with transforming growth factor-beta (TGF-β) has been proven to minimize intestinal damage and facilitate regeneration after mucosal injury. In the present study, we evaluated the effects of oral TGF-β2 supplementation on intestinal structural changes, enterocyte proliferation and apoptosis following methotrexate (MTX)-induced intestinal damage in a rat and in a cell culture model. Caco-2 cells were treated with MTX and were incubated with increasing concentrations of TGF-β2. Cell apoptosis was assessed using FACS analysis by annexin staining and cell viability was monitored using Trypan Blue assay. Male rats were divided into four experimental groups: Control rats, CONTR- TGF-β rats were treated with diet enriched with TGF-β2, MTX rats were treated with a single dose of methotrexate, and MTX- TGF-β rats were treated with diet enriched with TGF-β2. Intestinal mucosal damage, mucosal structural changes, enterocyte proliferation and enterocyte apoptosis were determined at sacrifice. Real Time PCR and Western blot were used to determine bax and bcl-2 mRNA, p-ERK, β-catenin, IL-1B and bax protein expression. Treatment of MTX-pretreated Caco-2 cells with TGF-B2 resulted in increased cell viability and decreased cell apoptosis. Treatment of MTX-rats with TGF-β2 resulted in a significant increase in bowel and mucosal weight, DNA and protein content, villus-height (ileum), crypt-depth (jejunum), decreased intestinal-injury score, decreased level of apoptosis and increased cell proliferation in jejunum and ileum compared to the untreated MTX group. MTX-TGF-β2 rats demonstrated a lower bax mRNA and protein levels as well as increased bcl-2 mRNA levels in jejunum and ileum compared to MTX group. Treatment with TGF-β2 also led to increased pERK, IL-1B and β-catenin protein levels in intestinal mucosa. Treatment with TGF-β2 prevents mucosal-injury, enhances p-ERK and β-catenin induced enterocyte proliferation, inhibits enterocyte apoptosis and improves intestinal recovery following MTX-induced intestinal-mucositis in rats.Keywords
This publication has 35 references indexed in Scilit:
- TGF-β2 treatment enhances cytoprotective factors released from embryonic stem cells and inhibits apoptosis in infarcted myocardiumAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Perspectives on cancer therapy-induced mucosal injuryCancer, 2004
- The pathobiology of mucositisNature Reviews Cancer, 2004
- Gastrointestinal mucositis: a new biological modelSupportive Care in Cancer, 2004
- TGF‐β down‐regulates IL‐6 signaling in intestinal epithelial cells: Critical role of SMAD‐2The FASEB Journal, 2003
- 4-Hydroxynonenal and transforming growth factor-β1 expression in colon cancerMolecular Aspects of Medicine, 2003
- WNT Signaling and Lymphocyte DevelopmentCell, 2002
- Peptide growth factors in the intestineEuropean Journal of Gastroenterology & Hepatology, 2001
- Selective sparing of goblet cells and Paneth cells in the intestine of methotrexate-treated ratsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2000
- Localization of Transforming Growth Factor-β Receptor Types I, II, and III in the Postnatal Rat Small IntestinePediatric Research, 1999